4.3 Review

Maintenance therapy in newly diagnosed multiple myeloma: current recommendations

期刊

EXPERT REVIEW OF ANTICANCER THERAPY
卷 14, 期 5, 页码 581-594

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2014.884930

关键词

multiple myeloma; thalidomide; lenalidomide; bortezomib; maintenance

类别

向作者/读者索取更多资源

The recent availability of novel agents has substantially improved the outcomes of patients with Multiple Myeloma (MM). Achieving the deepest level of complete response and maintaining a sustained remission are important steps towards MM cure. To achieve this goal, consolidation and maintenance therapies are currently incorporated into the modern therapeutic paradigm. The excellent activity shown by new drugs has led to their investigational use as maintenance therapy. However, despite promising results of continuous treatment with the novel agents, consensus regarding maintenance therapy still lacks. This review will focus on maintenance therapy, offering an overview of the different strategies available in MM. The issue of continuous treatment in the light of new biological discoveries, including intra-clonal heterogeneity, will also be addressed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据